Pivotal bioVenture Partners Investment Advisor
Latest statistics and disclosures from Pivotal bioVenture Partners Investment Advisor's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PCVX, ARQT, TRVI, Avalyn Pharma, EVMN, and represent 66.92% of Pivotal bioVenture Partners Investment Advisor's stock portfolio.
- Added to shares of these 4 stocks: Avalyn Pharma (+$32M), TRVI, PCVX, AVTX.
- Started 1 new stock position in Avalyn Pharma.
- Reduced shares in these 5 stocks: ZBIO, OCS, ARQT, BOLT, MPLT.
- Sold out of its position in BOLT.
- Pivotal bioVenture Partners Investment Advisor was a net buyer of stock by $34M.
- Pivotal bioVenture Partners Investment Advisor has $308M in assets under management (AUM), dropping by 10.01%.
- Central Index Key (CIK): 0001844645
Tip: Access up to 7 years of quarterly data
Positions held by Pivotal bioVenture Partners Investment Advisor consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Pivotal bioVenture Partners Investment Advisor
Pivotal bioVenture Partners Investment Advisor holds 13 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Vaxcyte (PCVX) | 26.9 | $83M | +3% | 1.4M | 58.13 |
|
| Arcutis Biotherapeutics (ARQT) | 10.8 | $33M | -6% | 1.3M | 26.22 |
|
| Trevi Therapeutics (TRVI) | 10.6 | $33M | +12% | 1.7M | 18.65 |
|
| Avalyn Pharmaceuticals Com Shs | 10.3 | $32M | NEW | 967k | 32.92 |
|
| Evommune Com Shs (EVMN) | 8.3 | $26M | 1.9M | 13.29 |
|
|
| Maplight Therapeutics (MPLT) | 7.1 | $22M | 611k | 35.84 |
|
|
| Oculis Holding Ordinary Shares (OCS) | 6.8 | $21M | -10% | 1.5M | 13.87 |
|
| Bioage Labs (BIOA) | 5.2 | $16M | 653k | 24.51 |
|
|
| Immunome (IMNM) | 5.0 | $16M | 733k | 21.19 |
|
|
| Zenas Biopharma (ZBIO) | 4.0 | $13M | -17% | 491k | 25.38 |
|
| Avalo Therapeutics Com New (AVTX) | 2.6 | $8.0M | +46% | 434k | 18.48 |
|
| Rallybio Corp (RLYB) | 1.6 | $4.8M | 301k | 16.00 |
|
|
| Recursion Pharmaceuticals In Cl A (RXRX) | 0.7 | $2.2M | 596k | 3.67 |
|
Past Filings by Pivotal bioVenture Partners Investment Advisor
SEC 13F filings are viewable for Pivotal bioVenture Partners Investment Advisor going back to 2020
- Pivotal bioVenture Partners Investment Advisor 2026 Q2 filed Aug. 13, 2026
- Pivotal bioVenture Partners Investment Advisor 2026 Q1 filed May 14, 2026
- Pivotal bioVenture Partners Investment Advisor 2025 Q4 filed Feb. 13, 2026
- Pivotal bioVenture Partners Investment Advisor 2025 Q3 filed Nov. 13, 2025
- Pivotal bioVenture Partners Investment Advisor 2025 Q2 filed Aug. 13, 2025
- Pivotal bioVenture Partners Investment Advisor 2025 Q1 filed May 14, 2025
- Pivotal bioVenture Partners Investment Advisor 2024 Q4 filed Feb. 13, 2025
- Pivotal bioVenture Partners Investment Advisor 2024 Q3 filed Nov. 13, 2024
- Pivotal bioVenture Partners Investment Advisor 2024 Q2 filed Aug. 13, 2024
- Pivotal bioVenture Partners Investment Advisor 2024 Q1 filed May 14, 2024
- Pivotal bioVenture Partners Investment Advisor 2023 Q4 filed Feb. 13, 2024
- Pivotal bioVenture Partners Investment Advisor 2023 Q3 filed Nov. 13, 2023
- Pivotal bioVenture Partners Investment Advisor 2023 Q2 filed Aug. 11, 2023
- Pivotal bioVenture Partners Investment Advisor 2023 Q1 filed May 12, 2023
- Pivotal bioVenture Partners Investment Advisor 2022 Q4 filed Feb. 13, 2023
- Pivotal bioVenture Partners Investment Advisor 2022 Q3 filed Nov. 10, 2022